Novartis, CH0012005267

Novartis stock sits at EUR 136.79 ahead of October 27 results

Published on 10/21/2026 at 10:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novartis stock costs EUR 136.79 on October 21, 2026 versus the Xetra close. Q3 estimates call for USD 14.55 billion revenue on October 27.

Results and pipeline dates

Novartis schedules third-quarter results for October 27, 2026.
Second-quarter net sales reached USD 14.41 billion, up 3.00 percent year over year.
Novartis stock trades at EUR 136.79 at 10:20 a.m. CEST at Lang & Schwarz on October 21, 2026, 0.23 percent above the Xetra close of October 20, 2026.

Pharmatechniker an Tablettenpresse, dokumentarische SW-Fotografie mit Industrieatmosphäre — Novartis AG CH0012005267 – Pharmatechniker bedient eine industrielle Tablettenpresse in dokumentarischer Schwarzweißfotografie, Illustration mit AI erstellt.

Novartis (ISIN CH0012005267) was trading at EUR 136.79 at Lang & Schwarz on October 21, 2026, at 10:20 a.m. CEST, up 0.23 percent versus the Xetra close of October 20, 2026 at EUR 136.48. Novartis has scheduled a Remibrutinib investor call for October 23 and third-quarter results for October 27, 2026.

Results are the next test

The October 27 release will cover the third quarter and nine months of 2026 in Basel. MarketBeat expects revenue of USD 14.55 billion and earnings per share of USD 2.25, compared with USD 14.36 billion and USD 2.25 in the same quarter a year earlier, respectively, according to MarketBeat. The revenue estimate implies 1.32 percent year-over-year growth, while the earnings-per-share estimate is unchanged.

Novartis enters that report with a mixed second-quarter base. Form 6-K data summarized by Ticker Scout show Q2 net sales of USD 14.41 billion, up 3.00 percent from USD 14.05 billion a year earlier, while net income fell 19.00 percent to USD 3.26 billion. Core operating income was USD 5.94 billion, with a 41.20 percent margin versus 42.20 percent in the prior-year quarter.

Three dated milestones for Novartis

On October 7, 2026, Novartis received FDA approval for Rhapsido as a first treatment for symptomatic dermographism, according to the company investor page. On October 19, 2026, the company discontinued the mid-stage Fabhalta lupus nephritis trial for strategic reasons, as reported by MarketScreener. The next milestone is the October 23 Remibrutinib call, followed by the October 27 results release.

What will October 27 test?

The central question is whether volume-led growth can offset generic competition and price pressure. In the second quarter, Novartis cited 18 percentage points of volume growth against 14 percentage points from generic competition and 3 percentage points from price erosion, while reaffirming low-single-digit sales growth and a low-single-digit decline in core operating income for full-year 2026, according to Ticker Scout.

Dates set the near-term frame

The Remibrutinib in multiple sclerosis investor call is scheduled for October 23, 2026, and the third-quarter results webcast is set for October 27, 2026, at 1:00 p.m. CET, according to the Novartis investor calendar. These dates give investors two separate updates on the pipeline and operating performance.

Stock holds above the Xetra close

The euro quote is 0.23 percent above the October 20 Xetra close, leaving the daily move below the 1.00 percent threshold used for a directional headline. The market value shown for October 20 was EUR 291.5 billion.

Novartis was trading at EUR 136.79 at Lang & Schwarz on October 21, 2026, at 10:20 a.m. CEST, 0.23 percent above the Xetra close of October 20, 2026 at EUR 136.48. The further course of trading is shown by the continuously updated real-time quote of Novartis stock.